Having raised the full-year sales guidance for Caplyta (lumateperone) a week ago, Intra-Cellular Therapeutics has reported positive topline data from a Phase III trial of the therapy for prevention in relapse in schizophrenia patients.
The trial, Study 304 (NCT04959032), met its primary endpoint of time to relapse during the 26-week double-blind treatment phase, with Caplyta treatment associated with a 63% reduction in the risk of relapse compared to the placebo.
Caplyta is Intra-Cellular鈥檚 only marketed therapy. Last year, the drug generated $462.2m in sales, and the company expects聽net product sales for Caplyta in 2024 to be between $665m and $685m, as per the company鈥檚 financials. GlobalData expects therapy sales to maintain an upward trajectory and generate over $3bn in sales by 2030.
GlobalData is the parent company of Pharmaceutical Technology.
The multicenter, parallel-group Phase III study enrolled 228 patients. All participants were treated with 42mg Caplyta in an 18-week open-label period before being randomised to receive either Caplyta or placebo as part of the double-blind treatment phase. The time to relapse was significantly longer in the Caplyta group compared to the placebo group, the study鈥檚 primary endpoint.
The rate of relapse was lower at 16.4% in the treatment group compared to 38.6% seen in the placebo group. The trial also met its secondary endpoint, with Caplyta treatment being linked with better treatment discontinuation rates during the double-blind phase.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataCaplyta is a butyrophenone antipsychotic. It was first approved by the US Food and Drug Administration (FDA) as a treatment for adults with schizophrenia in 2019. In 2022, the US regulatory agency expanded Caplyta鈥檚 approval to include treatment of depressive episodes associated with bipolar I or II disorder.
鈥淭he control of symptoms and the prevention of relapses is critical to improving long-term patient outcomes. We are very pleased that the results from Study 304, a randomized withdrawal trial, demonstrated efficacy along with favourable safety and tolerability which support the benefit of continued long-term treatment with Caplyta鈥� said Dr. Suresh Durgam, executive VP and chief medical officer at Intra-Cellular Therapies.
Intra-Cellular intends to expand Caplyta’s label in the US. The company plans to file for a supplemental new drug application (sNDA) with the US FDA for Caplyta as an (MDD) in Q4 2024. Intra-Cellular is also evaluating the therapy in paediatric patients with schizophrenia and bipolar disorders in a Phase III trial (NCT06229210). The open-label study is currently recruiting participants and is expected to enrol about 500 patients under 18 years of age.
